ANNOUNCEMENT

MedCity CONVERGE July 9-10 in Philly gathers payers, providers, medtech, pharma, digital health, policymakers & more.

Topic: hematology

Therapeutic could improve hemophilia B patients’ quality of life with reduced jabs

Therapeutic could improve hemophilia B patients’ quality of life with reduced jabs

January 21, 2013 11:25 am by | 0 Comments

A drug developer has initiated enrollment for a phase 3 trial for a hemophilia therapeutic that could reduce the frequency that people with the rare blood disorder need to take ... Read more
Will new genetic signatures lead to customized prostate cancer tests?

Will new genetic signatures lead to customized prostate cancer tests?

October 9, 2012 12:02 am by | 0 Comments

LONDON (Reuters) - Scientists have found two distinct genetic "signatures" for prostate cancer that may help doctors predict which patients have aggressive tumors, and designed experimental blood tests to read ... Read more
Novo Nordisk’s hemophilia treatment ‘blockbuster’ could turn into a total bust

Novo Nordisk’s hemophilia treatment ‘blockbuster’ could turn into a total bust

August 10, 2012 1:16 pm by | 0 Comments

Denmark's Novo Nordisk could be a few months away from dropping a drug expected to replace crucial blood treatment Novoseven and seen as a potential blockbuster, the company said on ... Read more
Indiana blood management consulting company bought by Mediware

Indiana blood management consulting company bought by Mediware

August 6, 2012 11:01 am by | 0 Comments

Mediware Information Systems, Inc. (Nasdaq: MEDW) today announced plans to acquire the assets of Indianapolis-based Strategic Healthcare Group LLC (SHG), a leading provider of blood management consulting, education and informatics ... Read more
Celgene submits NDA for multiple myeloma, forges personalized medicine collaboration

Celgene submits NDA for multiple myeloma, forges personalized medicine collaboration

April 26, 2012 1:43 pm by | 0 Comments

Celgene (NASDAQ:CELG) has submitted a new drug application to the U.S. Food and Drug Administration for pomalidomide, a drug designed for multiple myeloma that does not respond to therapies.Since the ... Read more
Oral anemia drug meets primary endpoints in phase 2 trial

Oral anemia drug meets primary endpoints in phase 2 trial

April 5, 2012 2:54 pm by | 0 Comments

A once-daily oral anemia drug from Akebia Therapeutics met its primary endpoint in a phase 2a trial of chronic kidney disease patients.The successful 42-day trial of the drug, now called ... Read more
Hemophilia therapeutic from CSL Behring gets orphan drug status

Hemophilia therapeutic from CSL Behring gets orphan drug status

February 16, 2012 3:24 pm by | 0 Comments

A drug therapy for hemophilia patients developed by CSL Behring has been given orphan drug status by U.S. regulators.The hemophilia therapeutic from CSL Behring, a plasma protein therapeutics producer in ... Read more
Celgene invests $15 million for closer collaboration with cancer drug co.

Celgene invests $15 million for closer collaboration with cancer drug co.

February 9, 2012 11:27 am by | 0 Comments

Celgene (NYSE:CELG) has made a $15 million strategic investment in a cancer drug developer, which gives it a seat on the company’s board and opens up collaboration opportunities down the ... Read more
Blood bank middleman General Blood raises $650,000

Blood bank middleman General Blood raises $650,000

July 20, 2011 11:39 am by | 0 Comments

A Minneapolis company that serves as a matchmaker for hospitals and blood banks is seeking $1 million, according to a regulatory filing.General Blood has already raised $650,000.The startup’s website says ... Read more
Anemia treatment moves forward, Akebia raises $22 million for trials

Anemia treatment moves forward, Akebia raises $22 million for trials

April 26, 2011 9:10 am by | 0 Comments

Akebia Therapeutics has closed a $22 million series B round of investment that will take the company through a pair of phase 2b trials of its oral anemia drug.The funding ... Read more
Akebia gets positive results from latest oral anemia drug trial

Akebia gets positive results from latest oral anemia drug trial

October 6, 2010 9:51 am by | 0 Comments

Akebia Therapeutics Inc. has successfully completed a Phase 2a trial of its orally administered anti-anemia drug for kidney disease patients. ... Read more
Akebia begins Phase 2a trial of oral anemia drug

Akebia begins Phase 2a trial of oral anemia drug

July 22, 2010 11:31 am by | 0 Comments

Akebia Therapeutics Inc. has begun a Phase 2a clinical trial of its orally administered anemia drug.The company recently completed a Phase 1b trial of the drug, called AKB-6548, that showed ... Read more
Cincinnati's Akebia starts Phase 1b clinical trial for anemia drug

Cincinnati's Akebia starts Phase 1b clinical trial for anemia drug

February 26, 2010 3:03 pm by | 1 Comments

Small molecule discovery and development company Akebia Therapeutics Inc. has started a second Phase 1 clinical trial of its anemia drug--another baton hand-off in a race with big drug companies ... Read more
Akebia completes Phase I trial of anemia drug, looks toward licensing deal with large pharmaceutical firm

Akebia completes Phase I trial of anemia drug, looks toward licensing deal with large pharmaceutical firm

January 5, 2010 2:47 pm by | 0 Comments

The successful completion of the trial in healthy human volunteers is a major milestone and kicks off what's shaping up to be a big year for the fledgling Cincinnati company. ... Read more
Cincinnati’s Akebia Therapeutics races (as safely as possible) toward new anemia treatment

Cincinnati’s Akebia Therapeutics races (as safely as possible) toward new anemia treatment

October 13, 2009 9:45 am by | 4 Comments

Akebia's anemia drug, known only as AKB-6548, passed an important milestone recently when Akebia embarked on a Phase I clinical trial and the first steps toward bedside use. The pill ... Read more